NCT01260480Unknown2 期
A Prospective, Multicenter Study, to Evaluate the Efficacy and Safety of [18F]-ML-10, a Positron Emission Tomography (PET) Imaging Radiotracer, in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 60
- 试验地点
- 6
- 主要终点
- To characterize changes in [18F]-ML-10 uptake in the target lesion in response to chemoradiotherapy.
研究概览
简要总结
The purpose of this study is to determine whether [18F]-ML-10 used in conjunction with PET imaging is effective as an imaging tool for the early detection of response of oncological tumors in the lungs,head and neck to chemoradiation therapy.
The study will evaluate the potential of [18F]-ML-10 used in conjunction with PET imaging to distinguish early during the course of chemoradiation therapy between a tumor that responds to the therapy, and a tumor that does not respond to the therapy. Currently, this distinction is available to the physician several weeks or months after completion of therapy, using anatomical imaging (for example Computed Tomography [CT] or Magnetic Resonance Imaging [MRI]).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with either:
- •Newly diagnosed non small cell lung cancer (NSCLC) (Group A) who meet the following criteria:
- •Previously untreated, histologically or cytologically confirmed stage IIB, IIIA or IIIB disease, without evidence of distant metastases
- •A measurable primary tumor with at least one diameter > 2 cm or primary tumor extending to one or more lymph nodes which cannot be distinctively delineated as confirmed by a diagnostic quality chest CT performed within 4 weeks prior to initiation of the concurrent CRT.
- •Planned to receive concurrent chemoradiotherapy as definitive treatment. The radiation dose should not exceed 70 Gy.
- •Undergone the following minimum workup to confirm disease staging within 4 weeks prior to initiation of the concurrent CRT:
- •GBCA-enhanced Brain MRI or contrast enhanced CT if there are signs or symptoms suggesting brain metastases within the past 2 months.
- •If necessary to confirm stage of disease, an upper abdomen CT scan will be performed.
- •whole-body FDG PET/CT; OR
- •Newly diagnosed squamous cell carcinoma of the head and neck (SCCHN) (Group B) who meet the following criteria:
- •Previously untreated, histologically or cytologically confirmed (from the primary tumor and/or lymph nodes) stage III-IV disease without evidence of distant metastases.
- •A measurable (i) primary tumor with at least one diameter ≥2 cm and (ii) lymph node with at least one diameter ≥ 2 cm as confirmed by a diagnostic quality neck CT performed within 4 weeks prior to initiation of the concurrent CRT.
- •Planned to receive concurrent chemoradiotherapy as definitive treatment. The radiation dose should not exceed 70 Gy.
- •Have undergone the following minimum workup to confirm disease staging within 4 weeks prior to initiation of the concurrent CRT:
- •Whole-body FDG PET/CT.
- •Patients ≥ 18 years of age.
- •Able to comply with lying still during the PET/CT imaging session which may last for up to 3 hrs with intermediate breaks.
- •ECOG performance status of 0, 1 or
- •Adequate renal function and adequate hepatic function, as assessed by standard laboratory criteria and defined as:
- •Serum creatinine ≤ 1.2 times the Upper Limit of Normal (ULN).
- •Total bilirubin ≤ 1.5 times the ULN.
- •Asparagine aminotransferase (AST) and/or alanineaminotransferase (ALT) ≤ 2.5 times the ULN (grade 1 according to the NCI-CTCAE v.3).
- •Women of child-bearing potential must have a negative blood pregnancy test at screening and use an adequate and medically acceptable contraceptive method.
- •Willing and able to comply with the protocol requirements.
- •Able to provide written informed consent.
排除标准
- •Exclusion criteria specific to patients with NSCLC (Group A):
- •Predominant small cell carcinoma histology.
- •Pure bronchioalveolar cell carcinoma histology.
- •Treatment planned with chemotherapy other than a platinum-based doublet regimen.
- •Malignant pleural or pericardial effusions.
- •Any contraindication to perform CT with IV contrast agent.
- •Exclusion criteria specific to patients with SCCHN (Group B):
- •Histology other than squamous cell carcinoma.
- •Treatment planned with chemotherapy other than a platinum-based regimen.
- •Treatment planned with cetuximab.
- •Treatment with induction chemotherapy.
- •Any contraindication to CT with IV contrast agent.
- •Evidence of distant metastases.
- •Patients who, based on the investigator's judgment, have other unstable medical conditions that may preclude safe and complete study participation.
- •Treatment with any investigational drug, device or biologic agent within 30 days prior to administration of [18F]-ML-
- •Pregnancy or lactation.
结局指标
主要结局
To characterize changes in [18F]-ML-10 uptake in the target lesion in response to chemoradiotherapy.
时间窗: Between baseline and day 11 ± 1, and between baseline and day 18 ± 1
次要结局
- To assess the correlation between the changes in the uptake of [18F]-ML-10 in the target lesion and the changes in the anatomical dimensions of the target lesion.
- To perform additional analyses for all other lesions and lymph nodes with at least one diameter ≥ 2 cm treated by concurrent CRT.
- To assess the safety of [18F]-ML-10 administered to cancer patients receiving concurrent CRT.
- To identify at least one parameter, derived from the changes in [18F]-ML-10 uptake that can discriminate tumors responsive to treatment from tumors that are non-responsive.
研究者
研究点 (6)
Loading locations...
相似试验
终止
不适用
FLT-PET Imaging for MDSMDSAMLNCT01535456University of Wisconsin, Madison1
Unknown
2 期
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.Brain MetastasesSolid TumorsNCT00805636Aposense Ltd.30
已完成
1 期
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and BortezomibAdvanced CancerNCT01143779M.D. Anderson Cancer Center3
已完成
2 期
18F ML-10 for Early Detection of Response of Brain Metastases to WBRTSolid TumorsBrain MetastasesNCT00791063Aposense Ltd.10
已完成
早期 1 期
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HCAlzheimer DiseaseNCT01268020Institute for Neurodegenerative Disorders5